<DOC>
	<DOCNO>NCT02012959</DOCNO>
	<brief_summary>The purpose trial demonstrate tolvaptan effectively safely increase maintains serum sodium concentration child adolescent subject euvolemic hypervolemic hyponatremia .</brief_summary>
	<brief_title>Study Safety Effectiveness SAMSCA® ( Tolvaptan ) Children Adolescents With Euvolemic Hypervolemic Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Inclusion : Male female subject ≥ 4 week ( ≥44 week adjust gestational age ) &lt; 18 year old Subjects hospitalize euvolemic hypervolemic hyponatremia resistant initial standard background therapy Persistent euvolemic hypervolemic hyponatremia define document &lt; 130 mEq/L present least 48 h , evidence least 2 serum sodium assessment ( 12 h apart ) Ability maintain adequate fluid intake ( orally IV ) Ability take oral medication Ability comply requirement trial Completion trial specific inform consent/assent age appropriate Ability commit remain fully abstinent practice doublebarrier birth control require trial . Exclusion : Evidence hypovolemia intravascular volume depletion Serum sodium &lt; 120 mEq/L Use potent CYP3A4 inhibitor subject &lt; 12 kg moderate CYP3A4 inhibitor subject &lt; 6 kg Lacks free access water without ICUlevel fluid monitoring management History current diagnosis nephrotic syndrome Transient hyponatremia likely resolve Hyperkalemia eGFR &lt; 30 mL/min/1.73 m² Acute kidney injury Severe acute neurological symptom require intervention Prior treatment hyponatremia hypertonic saline within 8 hour qualify serum sodium assessment ; Urea , lithium , demeclocycline , conivaptan , tolvaptan within 4 day qualify serum sodium assessment ; treatment purpose increase serum sodium concurrent dose trial medication . Anuria urinary outflow obstruction , unless subject is/can catheterize History hypersensitivity and/or idiosyncratic reaction benzazepine benzazepine derivative Psychogenic polydipsia Uncontrolled diabetes mellitus ( define fast glucose &gt; 300mg/dL ) . Screening liver function value &gt; 3 x ULN Subjects cirrhosis meet following condition : major GI bleed within past 6 month , evidence active bleeding , platelet count &lt; 50,000 /μL , use concomitant medication know increase bleed risk Hyponatremia due result medication safely withdraw appropriately correct alternative therapy History drug medication abuse within 3 month prior screen current alcohol abuse Subjects require suspension formulation Hereditary Fructose Intolerance Has hyponatremia appropriately correct alternative therapy Is pregnant currently breastfeed Has medical condition could interfere evaluation trial objective subject safety Has participate another investigational drug trial last 30 day Weighs &lt; 3 kg Unable swallow tablet , suspension unavailable Is deem unsuitable trial participation opinion PI</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hyponatremia</keyword>
	<keyword>Euvolemic</keyword>
	<keyword>Hypervolemic</keyword>
	<keyword>Serum sodium</keyword>
	<keyword>Dilutional hyponatremia</keyword>
	<keyword>Electrolyte abnormality</keyword>
	<keyword>Electrolyte imbalance</keyword>
	<keyword>Metabolic disease</keyword>
</DOC>